Drugs / LiveSpo CLAUSY
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05812820 | Jul 2022 → Dec 2023 | diarrheal disease | National Children's Hospital, Vietnam | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LiveSpo CLAUSY | “Persistent diarrhea is a severe gastroenteric disease with relatively high risk of pediatric mortality in developing countries. We conducted a randomized, double-blind,...” PMID 38494525 ↗ Mar 2024 |
| Modality | Other / unclassified | “liquid-form Bacillus clausii spore probiotics (LiveSpo CLAUSY; 2 billion CFU/5 mL ampoule)” PMID 38494525 ↗ Mar 2024 |